Supriya Lifescience Limited has released its investor presentation for Q1 FY27, highlighting a robust 31% Year-over-Year (YoY) revenue growth to INR 1,897.5 Million. The company also reported EBITDA of INR 474.6 Million and PAT of INR 240.4 Million. The presentation details the business mix, regional performance, and key strategic initiatives, underscoring the company’s continued expansion and focus on profitability.
Q1 FY27 Investor Presentation Highlights
Supriya Lifescience Limited has officially released its investor presentation for the first quarter of the financial year 2027 (Q1 FY27), covering the period ended June 30, 2026. The presentation outlines the company’s financial performance and strategic progress during the quarter.
Key Financial Metrics
The company reported significant year-over-year growth in its top line, with Revenue from Operations reaching INR 1,897.5 Million, marking a substantial 31% increase YoY. This growth trajectory continues to be a key focus for the company.
Profitability metrics also saw shifts: EBITDA stood at INR 474.6 Million, reflecting an 8% YoY decrease. Profit Before Tax (PBT) was reported at INR 407.9 Million, showing a 14% YoY decrease. Consequently, Profit After Tax (PAT) was INR 240.4 Million, also down 31% YoY.
EBITDA and PAT Margins
In terms of margins, EBITDA Margins were 25.0% in Q1 FY27, a decrease from 35.6% in Q1 FY26, representing a reduction of 1,063 basis points YoY. Similarly, PAT Margins declined to 12.7% in Q1 FY27 from 24.0% in Q1 FY26, a reduction of 1,131 basis points YoY.
Regional Performance and Business Mix
The presentation also detailed the Business Mix Revenue Contribution by Region. Asia accounted for 39% of revenue in Q1 FY27, followed by Europe at 35%. LATAM contributed 20%, while North America and Others represented 1% and 3% respectively. This geographical diversification highlights the company’s global reach.
Therapeutic Area Contribution
In terms of therapeutic areas, Anesthetic remained the dominant segment, contributing 48% of revenue in Q1 FY27, down from 53% in Q1 FY26. Vitamins showed strong growth, increasing their share to 17% from 11% YoY. Other key segments include Anti-Histamine (9%), Anti-Asthmatic (9%), Analgesic (3%), Anti-Allergic (4%), and Anti-hypertensive (2%).
Company Overview and Future Outlook
The investor presentation also provided insights into the company’s business overview, journey so far, backward integrated business model, diversified geographic presence, advanced manufacturing capabilities, R&D strengths, CMO capabilities, complex chemistries expertise, regulatory achievements, awards, and key management team. The future outlook section outlines strategic plans for R&D centers, CMO/CDMO space, new markets, and capacity enhancement, signaling a continued focus on growth and innovation.
Source: BSE
